Amgen Reports Results of KYPROLIS (carfilzomib) and DARZALEX (daratumumab) in P-III CANDOR study for Patients with Relapsed or Refractory Multiple Myeloma
Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin’s Lymphoma
Shots:
- The P-III CANDOR study involves assessing of KYPROLIS (56 mg/m2) + dexamethasone + DARZALEX vs KYPROLIS and dexamethasone monothx in 466 relapsed or refractory multiple myeloma patients who have received one to three prior therapies
- P-III CANDOR study results: met its 1EPs of PFS, 37% reduction in the risk of disease progression or death in patients; mPFS was not reached in KdD vs 15.8 mos. @Kd; ORR (84.3% vs 74.7%); CR (28.5% vs 10.4%); MDR- @12 mos.CR (12.5% vs 1.3%); mOS not reached; will be presented at 61st ASH
- KYPROLIS (carfilzomib) has the capability to block proteasomes and can also cause cell death especially in myeloma cells and is approved in multiple areas including the US, Japan, Canada and EU. The P-III CANDOR study is initiated in a collaboration with Janssen and co-fund the trial
Click here to read full press release/ article | Ref: Amgen | Image: Twitter